WEGO

What WEGO does

WEGO (威高集团, Weigao Group) is a vertically integrated Chinese medical devices and pharmaceuticals conglomerate founded in 1988 and headquartered in Weihai, Shandong Province. The group operates across 18 product categories spanning blood purification (dialyzers, dialysis machines, blood lines, peritoneal dialysis solutions), orthopedics (spinal and joint implants), interventional devices (coronary stents including the XINSORB biodegradable stent, FFR pressure guidewires), surgical robotics (four-arm laparoscopic robot), pharmaceutical packaging (pre-filled syringes), endoscope systems, in vitro diagnostics, and medical informatization (HIS, EMR, smart nephrology SaaS, UDI traceability platform). WEGO holds over 3,000 patents, has conquered 21 'bottleneck' technologies previously dominated by foreign manufacturers, and offers 1,000+ product types across 200,000+ specifications. The Blood Purification Group holds #1 market share in China's dialyzer (32.5%) and blood tubing (31.8%) segments.

WEGO's business model combines direct enterprise sales (over 100 domestic sales offices and 180+ regional offices covering 30+ provinces) with large-scale medical commercial distribution (460,000+ m² of warehousing serving 70%+ of China's Class 3A hospitals and 50%+ of public medical institutions) and direct-to-patient service delivery (60+ owned dialysis centers and kidney hospitals). The group also operates medical informatization SaaS across 1,000+ hospitals and generates international revenue across 100+ countries through regional subsidiaries, distributors, and joint ventures such as ONEJECT and Waad Alseha. Four subsidiaries are publicly listed: Shandong Weigao Medical Polymer (Hong Kong, since 2004), Weigao Orthopaedic (688161.SH STAR Market, since 2021), Weigao Blood Purification (603014.SH Main Board, since May 2025), and Argon Medical Devices (US acquisition, 2017, $850M).

The group's strategic agenda centers on a 'Three Transformations' framework — industrial concept transformation, governance model transformation, and value embodiment transformation — operationalized through the newly established Yangtze River Delta Group in Shanghai (April 2024) and the Cloud Innovation Park (180,000 m², opened May 2025), which together drive the second growth curve focused on internationalization and C-end consumer health. Manufacturing spans 10+ Chinese provinces with 6+ million m² of facilities and 30,000+ employees. The Yangtze River Delta Group oversees the 1+2+3+6 operating model targeting overseas markets, while the Ruijin Hospital partnership (April 2026) anchors a flagship medical-engineering transformation platform.

Name

WEGO

Legal name

威高集团有限公司

Website

https://weigaoholding.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

WEGO (威高集团) is a vertically integrated Chinese medical devices and pharmaceuticals conglomerate founded in 1988, serving 6,000+ hospitals and 100+ countries across 18 product categories including blood purification, orthopedics, interventional devices, and surgical robotics.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345), Medical Equipment and Supplies Manufacturing (33911), Pharmaceutical Preparation Manufacturing (325412)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO)

Keywords

• Medical devices manufacturing
• Hemodialysis products
• Orthopedic implants
• Interventional cardiology devices
• Pharmaceutical packaging

Headquarters

HQ city

Weihai

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Manufacturing & Sales: Core revenue stream from manufacturing and selling over 1,000 types of medical devices and pharmaceuticals across 200,000+ specifications. Includes consumables (infusion sets, syringes, blood bags), capital equipment (dialysis machines, surgical robots), implants (orthopedic, cardiovascular), and pharmaceutical packaging (pre-filled syringes). Revenue model is primarily direct B2B/B2G sales to hospitals and distributors, supplemented by international export sales.
2. Medical Commercial Distribution: New Commercial Industry Group operates medical/pharmaceutical distribution, SPD in-hospital logistics, and supply chain services. Manages over 460,000 m² of warehousing and logistics space, serving 70%+ of China's Class 3A hospitals and 50%+ of public medical institutions. Revenue model is transactional distribution with supply chain service fees.
3. Medical Services (Dialysis Centers & Hospitals): Blood Purification Group operates 60+ dialysis centers and kidney hospitals. Patient survival rate close to 100%, with many recovering ability to work. By 2030, expected to directly treat 200,000 patients, with hospital collaborations extending to 1 million patients. Also includes Qifu Nursing Home (RMB 205 million investment, 13,000 m², 200+ beds) offering medical, rehabilitation, and elderly care services.
4. Medical Informatization & Digital Solutions: Digital Technology Group provides hospital informatization solutions (HIS, EMR, integration platform, HRP, DRG), smart nursing, smart nephrology SaaS, smart materials management. Services over 1,000 hospital customers across 30+ provinces. Revenue model includes software licensing, implementation services, and SaaS subscriptions.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

WEGO develops, manufactures, and distributes a comprehensive portfolio of medical devices and pharmaceuticals across 18 product categories spanning clinical care, orthopedics, blood purification, interventional cardiology, surgical robotics, pharmaceutical packaging, and in vitro diagnostics. The company operates a vertically integrated medical ecosystem that combines industrial manufacturing (1,000+ product types, 200,000+ specifications), commercial distribution (SPD in-hospital logistics serving 70%+ of China's Class 3A hospitals), and medical services (60+ dialysis centers, kidney hospitals, and nursing homes). Products are sold directly to hospitals and government procurement programs domestically and exported to 100+ countries through regional subsidiaries and channel partners.

Product overview

威高集团是一家全球医疗器械和医药创新型企业，提供覆盖生命全周期的医疗系统整体解决方案。公司产品组合涵盖18个主要产品类别：通用耗材、内分泌、医疗信息化、骨科、口腔、组织修复、血液净化、药包材、外科、手术机器人、全血采集、介入、体外诊断、辅助生殖、医用医疗设备、康复系列、内窥镜和药品。核心子公司包括威高血净（603014.SH，专注血液透析全产业链）和威高骨科（688161.SH，专注骨科植入物）。主要产品包括四臂手术机器人、DBB-EXA S血液透析设备、XINSORB生物可吸收支架、Premier 5.5脊柱钉棒系统、LONG系列麻醉机、电子内窥镜系统、植入式给药装置等高精尖医疗器械。公司已形成医疗工业、医疗商业、医疗服务业协同发展的全医疗生态圈，产品远销全球100多个国家和地区。

Differentiator

Problem solved

Functional benefit

Brands

• 洁瑞 (Jiere): Sub-brand under WEGO for general medical consumables and wound care products
• 威瑞 (Weirui)
• 威高骨科 (Weigao Ortho)
• 威高云行智创园
• 威高七福护理院 (Qifu Nursing Home)
• 海螺姑娘 (Hai Luo Gu Niang)

Products and services

• General Medical Consumables (通用耗材) Disposable infusion sets, safety injection products, and basic medical consumables with leading domestic market share in China. Targeted at hospitals, clinics, and medical institutions for routine clinical use.
• Blood Purification Products (血液净化) Full industry chain of blood purification products including dialyzers, blood tubing, dialysis machines, and peritoneal dialysis solutions. WEGO holds #1 market share in China (32.5% dialyzers, 31.8% tubing in 2023). Serves 6,000+ hospitals and dialysis centers including 1,000+ Class 3A hospitals. Listed subsidiary WEGO Blood Purification (603014.SH) raised RMB 10.9 billion at May 2025 IPO.
• Orthopedic Products (骨科) Spine, trauma, joint, sports medicine, bone repair materials, orthopedic surgical instruments, and PRP preparation/closed-wound negative pressure drainage kits. Listed subsidiary WEGO Orthopaedic (688161.SH on Shanghai STAR Market) covers the orthopedic implant and tissue repair field.
• Surgical Robots (手术机器人) Four-arm laparoscopic surgical robots and remote surgical robots for high-end surgical applications. Marketed to hospitals and surgical centers domestically and internationally (e.g., exported to Indonesia).
• Interventional Devices (介入) Interventional medical devices and consumables for coronary intervention, congenital heart disease, cerebrovascular disease, peripheral vascular disease, and cardiac electrophysiology. Includes the XINSORB fully biodegradable coronary stent (world's second company to commercialize this technology) and the Pressure Guidewire & FFR Measurement Device.
• Pharmaceutical Packaging (药包材) Pre-filled syringes and pharmaceutical packaging materials. WEGO is the first Chinese manufacturer to obtain the registration certificate for pre-filled syringe production. Serves pharmaceutical manufacturers and hospital pharmacies.
• Surgical Products (外科) Surgical instruments, energy products, suture and hemostasis series, biomaterials, and absorbable consumables. Includes ISO 6335-1:2026 and ISO 6335-2:2026 surgical stapler standards, RPGA absorbable sutures with EU MDR Class III certification, and PDO/PGLA sutures.
• Medical Informatization Solutions (医疗信息化) Smart hospital integrated solutions including HIS, EMR, integration platform, HRP and DRG systems, smart nursing, smart nephrology SaaS (智慧肾科SaaS), smart materials management, smart service, and smart cloud imaging. Serves over 1,000 hospital customers across 30+ provinces with software licensing, implementation services, and SaaS subscriptions.
• In Vitro Diagnostics (体外诊断) Immunoassay, biochemistry, coagulation, mass spectrometry, and molecular diagnostic instruments and reagents. Series of testing consumables and auxiliary reproductive consumables for clinical laboratories and diagnostic centers.
• Medical Equipment (医用医疗设备) High-end medical equipment including anesthesia systems, surgical lights, operating tables, LONG series anesthesia machines, and electronic endoscope systems for hospital operating rooms and intensive care units.
• Endocrinology Products (内分泌) Medical devices and diagnostic products for endocrinology, including injection devices, blood glucose monitoring, and related consumables for diabetes and endocrine disorder management.
• Dental Products (口腔) Dental medical devices and consumables for dental clinics, hospitals, and oral surgery centers.
• Tissue Repair Products (组织修复) Tissue repair and regenerative medicine products for surgical reconstruction, wound healing, and tissue regeneration applications.
• Whole Blood Collection Products (全血采集) Whole blood collection medical devices and consumables for blood banks, blood centers, and clinical transfusion services.
• Assisted Reproduction Products (辅助生殖) Medical devices and consumables for assisted reproductive technology (ART) procedures including IVF and embryo transfer equipment and consumables.
• Rehabilitation Products (康复系列) Medical rehabilitation equipment and devices for physical therapy, post-surgery recovery, and patient rehabilitation programs.
• Endoscopy Systems (内窥镜) Endoscope center integrated solutions and electronic endoscope systems for minimally invasive surgical procedures and diagnostic endoscopy.
• Pharmaceutical Products (药品) Pharmaceutical products manufactured by WEGO's Pharmaceutical Group subsidiary for hospital and clinical use.
• Dialysis Center Services and Kidney Hospitals WEGO Blood Purification Group operates 60+ dialysis centers and kidney hospitals providing hemodialysis treatment services to end-stage renal disease patients. Patient survival rate is close to 100%, with many patients recovering ability to work. By 2030, expected to directly treat 200,000 patients, with hospital collaborations extending to 1 million patients.
• Qifu Nursing Home (威高七福护理院) Medical-elderly care combined institution with RMB 205 million investment, 13,000 m² facility, and 200+ beds offering medical treatment, rehabilitation, and elderly care services. Targets aging populations and integrates with WEGO's broader medical ecosystem.
• Medical Commercial Distribution Services (SPD In-Hospital Logistics) Medical commercial distribution and SPD in-hospital logistics services managed through 460,000+ m² of warehousing and distribution space. Covers 70%+ of China's Class 3A hospitals and 50%+ of public medical institutions. Operates commercial distribution, SPD logistics, and medical informatization integration.

Quantifiable outcome

• Blood Purification market share: 32.5% in dialysisators, 31.8% in dialysis tubing — both ranked #1 in China (2023)
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered core and flagship.

• ONEJECTcoreChannel Partner/ Reseller/ Distributor · 7 May 2026International partner mentioned at WEGO's 2026 Global Partner Conference. ONEJECT collaborates with WEGO across surgical and other product categories, contributing to WEGO's international market expansion.
• Waad Alseha CompanycoreChannel Partner/ Reseller/ Distributor · 7 May 2026International partner at WEGO's 2026 Global Partner Conference. Serves as WEGO's distribution partner in Middle East markets.
• Argon Medical Devices (爱琅医疗)coreTechnology or Integration · 7 May 2026WEGO acquired US-based Argon Medical Devices for USD 850 million in 2017, introducing internationally advanced interventional technologies and expanding WEGO's global footprint. Argon remains an important subsidiary contributing to WEGO's interventional device portfolio.
• Shanghai Ruijin Hospital (上海交通大学医学院附属瑞金医院)flagshipStrategic or Co-development Partner · 1 April 2026Jointly established the 'Guangci-Sinan·WEGO Intelligent Medical Device Innovation Transformation Space' in Shanghai. Eight clinical-medical transformation projects were signed including bone marrow infusion system, flexible bone adhesive, AI-assisted shoulder replacement, minimally invasive surgical tools, and pancreas perioperative innovation. The partnership leverages Ruijin's clinical expertise and WEGO's engineering and manufacturing capabilities to accelerate medical device innovation from concept to commercialization.
• Jinan Nursing Vocational College (济南护理职业学院)coreStrategic or Co-development Partner · 1 January 2026WEGO and Jinan Nursing Vocational College co-organized the 2026 'WEGO Cup' Smart Medical Equipment Technology Skills Competition. The competition aligned with WEGO's actual production standards and industry best practices, providing students with professional internship qualifications and serving as a talent pipeline for WEGO's recruitment needs.
• Shandong Medical College (山东医学高等专科学校)coreStrategic or Co-development Partner · 12 November 2025Signed comprehensive school-enterprise cooperation agreement including: co-founding 'WEGO Industry College' with a '1.5+1.5' talent cultivation model, establishing a 'Medical-Engineering Order Training' program,共建 practice teaching base, and joint research in technology science. Students spend first 1.5 years at school and second 1.5 years at WEGO for practical training, with direct employment after graduation.
• National Technology Innovation Center for the Yangtze River Delta (长三角国家技术创新中心)flagshipStrategic or Co-development Partner · 16 May 2025Co-founded the 'Cloud-Run Medical-Engineering Joint Concept Verification Center' at WEGO's Cloud Innovation Park in Shanghai. Partners include multiple Shanghai-based research institutions, innovation centers, and biotech incubators working together on medical device innovation and transformation.
• DuPont China (杜邦中国)coreStrategic or Co-development Partner · 14 April 2024WEGO and DuPont China signed a strategic cooperation intention letter at CMEF 2024. DuPont will provide WEGO with more comprehensive and innovative packaging solutions in medical packaging. The partnership aims to strengthen mutual cooperation and trust across multiple product areas, driving joint innovation in medical device packaging technology.
• Terumo (泰尔茂)coreTechnology or IntegrationWEGO Blood Purification Group partnered with Terumo (泰尔茂) and Nikkiso (日机装) as two major international medical enterprises in the blood purification field. Partnerships focus on blood dialysis and peritoneal dialysis strategic directions, leveraging WEGO's local manufacturing and Terumo's international technology.
• Nikkiso (日机装)coreTechnology or IntegrationWEGO Blood Purification Group partnered with Nikkiso (日机装) and Terumo (泰尔茂) for blood purification technology. Nikkiso provides dialysis machine technology while WEGO handles local manufacturing and market development in China.

Scale indicators22 records

Recent moves13 records

Expansion highlights7 records

Market position

Competitive moat7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/wego-holding

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WEGO